{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-222818","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2026-05-14T11:36:49+00:00","discovered_at":"2026-05-14T11:40:01.293404+00:00","generated_at":"2026-05-14T11:40:32.198784+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pyxis Oncology Q1 2026 net loss $23.3M; MICVO data on track for mid-2026","bullets":["Net loss $23.3M ($0.37/share) vs $21.2M ($0.35/share) YoY; R&D expenses rose to $20.0M from $17.0M.","Cash and equivalents $42.5M; expected runway into Q4 2026.","MICVO Phase 1 monotherapy update in 2L+ R/M HNSCC (dose cap patients) on track for mid-2026.","MICVO + pembrolizumab Phase 1/2 combination dose escalation data in 1L R/M HNSCC expected 2H 2026.","Appointed Nelson Azoulay as Chief Business Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-222818","json":"https://secwatch.observer/filing/0001193125-26-222818.json","markdown":"https://secwatch.observer/filing/0001193125-26-222818.md","text":"https://secwatch.observer/filing/0001193125-26-222818.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526222818/0001193125-26-222818-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526222818/pyxs-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T11:40:32.198784+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}